CJC-1295 vs Ipamorelin

People type “CJC-1295 vs ipamorelin” into a search bar expecting a winner — a clear answer about which peptide builds more muscle, burns more fat, or is “stronger.” That framing sets you up for a disappointing answer, because these two compounds are not really competitors. They are two different tools that act on two different receptors, and the most common way they’re used is together. Understanding why is more useful than a scoreboard, so this page compares them honestly across five axes — mechanism, evidence, pharmacokinetics, side-effect profile, and US legal status in 2026 — and then explains what the comparison actually tells you.

Two different levers on the same system

Both peptides aim at the same end goal: getting your own pituitary gland to release more growth hormone (GH). Neither one is growth hormone, and neither supplies it. They are secretagogues — they signal the body to make its own. But they pull on two completely different levers.

CJC-1295 is a GHRH analog. It’s built on the natural GHRH backbone (GRF 1-29) with a few amino-acid substitutions to make it last longer and resist breakdown. It binds the pituitary’s GHRH receptor — the same “go” signal the hypothalamus normally sends — and raises the overall drive for GH release. Think of it as turning up the baseline.

Ipamorelin is a ghrelin-receptor agonist (it binds GHS-R1a, the same receptor the “hunger hormone” ghrelin uses). Instead of mimicking the hypothalamic GHRH signal, it triggers a separate, complementary release mechanism, producing a distinct pulse of GH. Crucially, it’s a selective one: it nudges GH release without meaningfully stirring up cortisol, prolactin, or appetite the way some older ghrelin-mimetics do.

So the foundational difference is this: CJC-1295 raises the floor; ipamorelin sharpens the spike. One is a tonic, baseline signal; the other is a punctual, selective trigger. They’re not redundant, and they’re not interchangeable — they push on different parts of the same pathway.

Note: This two-receptor design is the whole reason the “CJC-1295 + ipamorelin” stack exists. Pairing a GHRH analog with a ghrelin-receptor agonist is a deliberate attempt to hit the system from two angles at once. The pairing is covered in depth on the combo pages — here the point is just that “versus” undersells how often they’re run side by side.

The evidence: thin on both sides, but thin in different ways

This is where an honest comparison gets interesting, because the human evidence is genuinely asymmetric — and not in the direction the marketing implies.

CJC-1295 has a small but positive human trial behind it: a 2006 phase-1 study (Teichman and colleagues) that measured what happens to blood markers after dosing. It showed a dose-dependent, sustained rise in GH and IGF-1, with a notably long half-life. That’s a real, peer-reviewed result. The catch is what it measured: blood levels, not bodies. No participant’s muscle, fat, strength, or appearance was an endpoint. It proved the drug does the upstream thing it’s supposed to do — raise GH/IGF-1 — and stopped there.

Ipamorelin has the opposite kind of footnote. Its only completed human efficacy trial wasn’t an anti-aging or physique study at all — it was a hospital trial for postoperative ileus (sluggish gut after surgery). That trial missed its primary endpoint and was discontinued for lack of efficacy. Beyond that, ipamorelin’s human story is largely the demonstration that it acutely releases GH — a mechanism result, not an outcome.

Put those side by side and a strange picture emerges. If you’re scoring “which has a human trial that worked,” CJC-1295 has a positive PK/PD study and ipamorelin has a negative efficacy study. But that scoreline is misleading too, because neither result is about the things people actually want — building muscle, losing fat, looking younger, sleeping better. CJC’s win is on a surrogate marker; ipamorelin’s loss is on an unrelated indication. For the body-composition and anti-aging claims that drive most searches, both peptides rest on mechanism and self-report, not controlled human outcome data.

That symmetry of absence is the single most important thing this comparison can tell you. Whichever you favor, you’re favoring it on theory.

Pharmacokinetics: sustained vs pulsatile

The practical “feel” difference between the two comes down to timing, and here CJC-1295 has an extra wrinkle: it exists in two functionally different forms.

• CJC-1295 with DAC (Drug Affinity Complex) is the long-acting version. The DAC modification lets it circulate for days, holding GH/IGF-1 elevated in a sustained, tonic way. One signal, long tail.
• CJC-1295 without DAC — frequently sold under the name Mod GRF 1-29 — is short-acting, producing a brief pulse closer to natural GHRH, then clearing within roughly half an hour.

Ipamorelin is short-acting by nature: it produces a quick, self-limiting GH pulse and is gone. It does not, on its own, keep IGF-1 chronically elevated.

This matters for the comparison because the “sustained vs pulsatile” question is partly a within-CJC question, not just a CJC-vs-ipamorelin one. The version of CJC-1295 someone is talking about changes the answer entirely. A common theoretical argument in the clinic favors pairing no-DAC CJC-1295 with ipamorelin specifically to preserve the body’s natural pulse pattern — two short signals that rise and fall — rather than flattening it with a multi-day DAC tail. Whether that pulsatility argument translates into better real-world outcomes is, again, not something a human trial has settled.

Note: Because “CJC-1295” can mean either a multi-day drug or a 30-minute one depending on the DAC, any comparison that doesn’t specify which version is comparing a moving target. If you read a claim about “CJC-1295,” your first question should be: DAC or no-DAC?

Side effects and selectivity

Ipamorelin’s headline selling point in the comparison is selectivity. Because it’s a clean GHS-R1a agonist, it tends not to spill over into cortisol release, prolactin elevation, or appetite stimulation — problems associated with some earlier, less selective ghrelin-mimetics. In controlled settings it’s been described as well tolerated, with the usual caveats of injectable peptides (injection-site reactions, occasional headache, water retention).

CJC-1295’s profile, from its phase-1 data, was also relatively mild in the short term — flushing, injection-site reactions, headache, mild water retention, the kind of tingling associated with raised GH. Its distinctive concern is different: the sustained IGF-1 elevation of the DAC version. Chronically raised IGF-1 is a different physiological situation from a brief pulse, and it’s the reason responsible providers monitor IGF-1 against age-appropriate ranges rather than treating “higher” as “better.”

Two honest cautions cut across both:

1. “Fewer side effects” is not the same as “safe” when the product is unverified. A selective peptide manufactured to unknown purity, in a vial of unknown concentration, bought outside the legal supply chain, is not made safe by the molecule’s clean receptor profile. The contaminant doesn’t care how selective the active ingredient is.
2. Most real-world “side-effect reports” can’t separate the peptide from the stack. Since these two are so often run together (and frequently alongside other compounds), an experience attributed to “ipamorelin” or “CJC-1295” is usually a combined-effect report.

So on selectivity, ipamorelin has a genuine theoretical edge. On safety overall, the limiting factor for both is the same gray-market product-quality problem — not the receptor pharmacology.

US legal status in 2026: a tie at the bottom

Here the comparison collapses into one shared answer, and it’s the part most affected by out-of-date information online.

Neither CJC-1295 nor ipamorelin is an FDA-approved drug. Both were caught up in the FDA’s peptide-compounding review. Both were removed from the restricted Category 2 list — which many vendors trumpet as “now legal.” But removal from Category 2 is not authorization. The substances then went to the Pharmacy Compounding Advisory Committee (PCAC), and the committee recommended against including either one on the list that would let 503A pharmacies compound them cleanly. In the votes, both were rejected decisively.

That leaves both in the same regulatory limbo as of mid-2026: out of the “significant safety risk” bucket, but not placed in Category 1, not authorized for compounding, and not on the agenda for the July 2026 PCAC meeting that’s reviewing the rest of the peptide cohort. A licensed provider can, in principle, write a prescription; a compounding pharmacy has no clean legal basis to fill it. The broader peptide reclassification story is genuinely in motion — but for these two specific compounds, the door the others are waiting on has, for now, already been closed.

So on access, it’s a tie, and not a good one. If you’re comparing CJC-1295 and ipamorelin on “which can I actually obtain through a legitimate route,” the answer for both is: not cleanly. (The GHRH-side compound that does have an open compounding pathway is sermorelin, which is why it keeps coming up as the legal-route alternative — see the sermorelin comparison linked below.)

This status is current as of this page’s last update and is exactly the kind of thing that can change after the next FDA action, so treat any single date as a snapshot.

So which should you care about?

If the comparison has a verdict, it’s this: the useful question usually isn’t “which one,” it’s “either, and on what evidence.”

• They aren’t rivals. CJC-1295 sets baseline GH drive; ipamorelin adds a selective pulse. Clinical use typically combines them, so framing it as a duel misrepresents how they’re actually used.
• Their human evidence is thin on both sides — a positive surrogate-marker trial for CJC, a failed unrelated-indication trial for ipamorelin, and no body-composition outcome data for either.
• Ipamorelin’s real edge is selectivity (less cortisol/prolactin/appetite disturbance); CJC’s distinctive issue is sustained IGF-1 elevation that warrants monitoring.
• In 2026 their legal status is effectively identical and effectively closed for compounding, regardless of what vendor pages claim.

If you came here to choose a winner for a physique goal, the most honest takeaway is to step back one level: the evidence supporting either compound for muscle, fat, or anti-aging outcomes is extrapolation, not proof. Anyone who does pursue GH-secretagogue therapy should do it through a licensed provider who evaluates you, monitors IGF-1, and works within a legitimate supply route — not by deciding between two vials on the strength of a forum thread. The differences between CJC-1295 and ipamorelin are real and worth understanding, but they’re differences in job, not in winner.